α-(m-Chlorphenylamino)-phenylessigsaeure | 60561-75-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-(m-Chlorphenylamino)-phenylessigsaeure
• 英文别名: (3-Chloro-phenylamino)-phenyl-acetic acid；2-(3-chloroanilino)-2-phenylacetic acid
• CAS: 60561-75-3
• 化学式: C₁₄H₁₂ClNO₂
• mdl: MFCD04116961
• 分子量: 261.708
• InChiKey: BNCQAJOGWSGDNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  α-(m-Chlorphenylamino)-phenylacetamid 、 水 、 sodium hydroxide 以48%的产率得到
  参考文献：
  名称：

  BHATT S. B.; PARIKH A. R., CURR. SCI. (INDIA), 1976, 45, NO 15, 547

  摘要：

  DOI：

文献信息

• Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
  申请人：——

  公开号：US20010034359A1

  公开（公告）日：2001-10-25

  The present invention is directed to compositions that inhibit the nonenzymatic glycation of albumin, as well as methods of using compounds that inhibit albumin glycation for the treatment of glycation-related pathologies.

  本发明涉及抑制白蛋白非酶促糖基化的组合物，并使用抑制白蛋白糖基化的化合物治疗糖基化相关病理的方法。
• ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES
  申请人：EXOCELL, INC.

  公开号：EP1242069A2

  公开（公告）日：2002-09-25
• 非酵素的糖化を防止し、糖化に関連する病気治療に使用され得るアルブミン結合化合物
  申请人：エグゾセル・インコーポレーテッド

  公开号：JP4833468B2

  公开（公告）日：2003-02-04
• Methods and Composition Comprising 2-[(3-Chlorophenyl)Amino] Phenylacetic Acid for Alzheimer's Disease
  申请人：Cohen Margo P.

  公开号：US20080255236A1

  公开（公告）日：2008-10-16

  The present invention is directed to a method of preventing or arresting the progression of Alzheimer's disease by administering to a patient having Alzheimer's disease a composition comprising an amount of 2-[(3-chlorophenyl)amino]phenylacetic acid, or a pharmaceutically acceptable salt thereof, sufficient to elicit a prophylactic or therapeutic effect. In some embodiments, the composition is administered orally, transdermally, intravenously, intrathecally, or by suppository. In some embodiments, the composition comprises a pharmaceutically acceptable carrier.
• LONG-ACTING AND CONTROLLED RELEASE FORMULATIONS OF 2-[(3-CHLOROPHENYL) AMINO] PHENYLACETIC ACID
  申请人：Cohen Margo P.

  公开号：US20140030325A1

  公开（公告）日：2014-01-30

  Formulation of long-acting and controlled release preparations of 2-[(3-chlorophenyl)amino] phenylacetic acid (23CPPA) are disclosed. Long-acting preparations comprise a slow-release formulation coated onto a pharmaceutical composition containing 23CPPA, protect against gastric irritation, slow absorption of 23CPPA, extend release of 23CPPA, protect against excessively high 23CPPA blood concentrations, and prolong maintenance of blood concentrations of 23CPPA after administration. Controlled release formulations comprise (a) a core element which is a compressed tablet containing a therapeutic dose of 23CPPA and an amount of a solubility modulating substance that controls the release of said 23CPPA in order to provide a therapeutic level over a period of about 24 hours; and (b) on the outer surface of the core element, a sufficient amount of an enteric coating that causes the 23CPPA to release at a rate that permits the use of once-a-day dosing to maintain steady state therapeutic levels of 23CPPA.